Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

This study has been terminated.
(Drug availability issues)
Information provided by (Responsible Party):
City of Hope Medical Center Identifier:
First received: October 5, 2005
Last updated: March 30, 2015
Last verified: March 2015

RATIONALE: Antiviral drugs, such as nelfinavir mesylate, may help prevent cancer cells from spreading.

PURPOSE: This phase I/II trial is studying the side effects and best dose of nelfinavir mesylate and to see how well it works in treating patients with recurrent, metastatic, or unresectable liposarcoma.

Condition Intervention Phase
Adult Liposarcoma
Recurrent Adult Soft Tissue Sarcoma
Stage III Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma
Drug: nelfinavir mesylate
Procedure: biopsy
Other: laboratory biomarker analysis
Other: pharmacological study
Genetic: gene expression analysis
Genetic: western blotting
Genetic: reverse transcriptase-polymerase chain reaction
Other: immunoenzyme technique
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Nelfinavir in Liposarcoma

Resource links provided by NLM:

Further study details as provided by City of Hope Medical Center:

Primary Outcome Measures:
  • Dose Limiting Toxicity (DLT) (Phase I) [ Time Frame: 4 weeks from start of treatment, up to 2 years ] [ Designated as safety issue: Yes ]
    DLT is defined as any grade III toxicity not reversible to grade II or less within one week, or any grade IV toxicity. Hyperlipidemia, hyperglycemia, nausea, vomiting and diarrhea are not DLTs unless they are uncontrolled grade 3/4. Dose delays lasting more than 2 weeks due to toxicity are considered a DLT. Dose escalation schedule for nelfinavir: 1250 mg bid ; 1500 mg bid; 2125 mg bid; 3000 mg bid; 4250 mg bid ; 6000 mg bid ; 8500 mg bid ; 12000 mg bid

  • Maximum Tolerated Dose (MTD) (Phase I) [ Time Frame: 4 weeks from start of treatment, up to 2 years ] [ Designated as safety issue: Yes ]
    The highest dose tested in which fewer than 33% of patients experience an attributable DLT to the study drug, when at least 6 patients are treated at that dose and are evaluable for toxicity. If PK analysis of 3 patients treated at 4250 mg bid and 3 patients at 3000 mg bid confirms that the first dose area under the curve and Cmax of nelfinavir does not increase appreciably at doses greater than 1875 mg BID then 3000 mg BID will be deemed the MTD.

  • Overall Response Rate (Phase II) [ Time Frame: After 3 cycles of treatment, up to 2 years. ] [ Designated as safety issue: No ]
    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Enrollment: 29
Study Start Date: March 2006
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Patients receive oral nelfinavir mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: nelfinavir mesylate
Given orally
Other Name: Viracept
Procedure: biopsy
Correlative studies
Other Name: biopsies
Other: laboratory biomarker analysis
Correlative studies
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies
Genetic: gene expression analysis
Correlative studies
Genetic: western blotting
Correlative studies
Other Names:
  • Blotting, Western
  • Western Blot
Genetic: reverse transcriptase-polymerase chain reaction
Correlative studies
Other Name: RT-PCR
Other: immunoenzyme technique
Correlative studies
Other Name: immunoenzyme techniques

Detailed Description:


I. To assess the toxicity and tolerance of nelfinavir in patients with liposarcoma.

II. To define the maximum tolerated dose (MTD) of nelfinavir when given daily as a single agent and to describe the toxicities at each does studied.

III. To evaluate the pharmacokinetics of nelfinavir. IV. To assess the response rate and progression free survival in patients with liposarcoma treated with nelfinavir.

V. To evaluate the expression and activity of certain proteins in the tumors of patients entered on this study, which may be important to the cytotoxicity of nelfinavir (SREBP-1, p21, NFkB (NFkappaB), caspase 3).

OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

Patients receive oral nelfinavir mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Patients must have histologically confirmed liposarcoma, which is recurrent, metastatic or unresectable
  • There is no limit to prior chemotherapy regimens; in addition, patients may have prior radiation
  • All patients must have measurable disease, defined as lesions that can be accurately measured in at least one dimension (>= 20 mm with conventional techniques or >= 10mm with spiral CT scan); pleural effusions and ascites will not be considered measurable, but may be present in addition to the measurable lesion(s)
  • ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2; patients should have an expected survival of at least 3 months
  • Absolute neutrophil count >= 1,000/ul
  • Platelets >= 75000/ul
  • Total bilirubin =< 2.0 g/dl
  • AST(SGOT)/ALT(SGPT) =< 2.0X institutional upper limit of normal
  • Brain metastasis is not an exclusion; however, patients are only eligible if they have had successful control of the brain tumor(s) by surgery or radiation therapy
  • All prior therapy must have been completed at least 3 weeks prior to the patient's entry on this trial
  • No concurrent chemotherapy, radiotherapy, immunotherapy or other investigational agents
  • Women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; should a women become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • Ability to understand and willingness to sign a written informed consent document


  • Patient has had prior treatment with or is currently taking a protease inhibitor
  • Patients enrolled cannot be on the following medications: cisapride, triazolam, midazolam, ergot derivatives, amiodarone, quinidine, dihydropyridine calcium antagonists (amlodipine, felodipine, isradipine, nicardipine, nifedipine, nimodipine, and nisoldipine), sildenafil, dilantin, rifampin or oral contraceptives
  • Uncontrolled intercurrent illness
  • Patients must have recovered from any expected toxicities of previous chemotherapy or radiation therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00233948

United States, California
City of Hope Medical Center
Duarte, California, United States, 91010
South Pasadena Cancer Center
Pasadena, California, United States, 91030
Sponsors and Collaborators
City of Hope Medical Center
Principal Investigator: Warren Chow Beckman Research Institute
  More Information

No publications provided

Responsible Party: City of Hope Medical Center Identifier: NCT00233948     History of Changes
Other Study ID Numbers: 04090, NCI-2010-01263, CDR0000438712, FDA R01FD003006-03
Study First Received: October 5, 2005
Results First Received: February 2, 2015
Last Updated: March 30, 2015
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Adipose Tissue
Neoplasms, Connective and Soft Tissue
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
HIV Protease Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses processed this record on November 25, 2015